Book an appointment via WhatsApp: Message us on 211 850 0016 and our automated booking assistant will guide you through the process.
Book an appointment via WhatsApp 211 850 0016
Doctor - Home

Chronic Pain

rTMS in chronic pain: neuromodulation of the motor cortex as a therapeutic strategy for treatment-resistant pain syndromes.

Chronic pain is defined as pain that persists or recurs for more than 3 months, beyond the expected healing period. It includes heterogeneous conditions such as neuropathic pain, fibromyalgia, and chronic migraine. rTMS, especially targeting of the primary motor cortex (M1), is recognized as a valid therapeutic option for treatment-resistant chronic pain syndromes. Learn more about how rTMS works.

Why it matters

Chronic pain is one of the most common causes of disability and social exclusion worldwide. Pharmacotherapy, including opioids, anticonvulsants, and tricyclic antidepressants, has significant limitations: dependence, tolerance, and side effects. Neuropathic pain in particular, due to central sensitization, often responds poorly to conventional analgesics. rTMS contributes non-invasive analgesia through modulation of central pain-processing mechanisms.

Mechanism

  • Central sensitization: In chronic pain, central neural circuits, including the thalamus, somatosensory cortex, and anterior cingulate cortex, are in a state of hyperexcitability. rTMS can help reverse this dysfunction by enhancing neuroplastic mechanisms.
  • M1 as a target: High-frequency stimulation (HF, 5–20 Hz) of the primary motor cortex (M1), following motor threshold measurement, activates descending analgesic pathways from the periaqueductal gray (PAG), increasing endogenous opioid activity.
  • DLPFC as a secondary target: The DLPFC may be used adjunctively when depressive or anxiety symptoms coexist with chronic pain.
  • Neuropathic pain: Stronger evidence exists for post-herpetic neuralgia, trigeminal neuralgia, central post-stroke pain, and fibromyalgia.

Clinical significance

Meta-analyses and IFCN guidelines by Lefaucheur et al. in 2014 and 2020 classify HF-rTMS over M1 as Level A evidence for neuropathic pain of central or peripheral origin. Studies in fibromyalgia show reductions in VAS pain scores of approximately 30–50% after a full treatment course. Effects often relapse after weeks to months, which is why maintenance-session protocols may be considered. See more frequently asked questions about pain treatment.

Explicit relations (Entity Graph)

  • Chronic pain mechanism: central sensitization.
  • Main rTMS target in chronic pain: primary motor cortex (M1).
  • HF-rTMS over M1 has Level A evidence in IFCN guidelines for neuropathic pain.
  • Analgesic mechanism of rTMS over M1: activation of PAG and descending opioid pathways.
  • Fibromyalgia response to rTMS over M1: VAS reduction of approximately 30–50%.
  • Neuropathic pain types with stronger evidence include post-herpetic neuralgia, central post-stroke pain, and trigeminal neuralgia.
  • Chronic pain may coexist with depression and anxiety, in which case a DLPFC protocol may be used as a secondary approach.
  • rTMS for chronic pain may require maintenance protocols.

References

  1. Lefaucheur JP, André-Obadia N, Antal A, et al. (2014). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clinical Neurophysiology.
  2. Lefaucheur JP, Aleman A, Baeken C, et al. (2020). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update. Clinical Neurophysiology.
  3. O’Connell NE, Marston L, Spencer S, et al. (2018). Non-invasive brain stimulation techniques for chronic pain. Cochrane Database of Systematic Reviews.